Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped down prior to trading on Thursday . The stock had previously closed at $32.36, but opened at $31.33. Dyne Therapeutics shares last traded at $31.93, with a volume of 67,167 shares.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $43.00 to $35.00 in a research note on Thursday. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler reiterated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.60.

Dyne Therapeutics Trading Down 1.2 %

The company has a 50-day moving average price of $36.34 and a two-hundred day moving average price of $34.66. The stock has a market cap of $2.69 billion, a P/E ratio of -7.74 and a beta of 1.05.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at approximately $3,405,524.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 158,975 shares of company stock valued at $5,693,789 over the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. purchased a new position in Dyne Therapeutics during the 1st quarter worth $140,666,000. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after buying an additional 2,663,910 shares during the period. Artal Group S.A. raised its holdings in shares of Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Dyne Therapeutics by 10.4% in the second quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock worth $42,881,000 after acquiring an additional 114,888 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.